Metformin and other biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels. Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice and this may contribute to its mode of action possibly through an effect on glucagon-like peptide-1 secretion.
Research Article: Drug Designing: Open Access
Research Article: Drug Designing: Open Access
Editorial: Drug Designing: Open Access
Editorial: Drug Designing: Open Access
Editorial: Drug Designing: Open Access
Scientific Tracks Abstracts: Journal of Developing Drugs
Keynote: Drug Designing: Open Access
Scientific Tracks Abstracts: Biochemistry & Pharmacology: Open Access
Accepted Abstracts: Drug Designing: Open Access